Latest Breaking News On - Maria ekdahl - Page 1 : vimarsana.com

Infant Bacterial Therapeutics AB (publ) Interim report January 1 - June 30, 2023

Message from the CEO Our Phase-III study, the largest of its kind ever conducted, is progressing across 88 hospitals in ten countries. We have now recruited 85% of the patients , and with the current.

United statesUnited kingdomMaria ekdahlStaffan stroEuropean patent officeData monitoring committeeAmerican journalSustained feeding toleranceExtraordinary general meetingBritish journalNasdaq stockholm

Infant Bacterial Therapeutics AB (publ) Interim report January 1

Infant Bacterial Therapeutics AB (publ) Interim report January 1
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesStaffan stroMaria ekdahlEuropean patent officeData monitoring committeeAmerican journalSustained feeding toleranceExtraordinary general meetingBritish journalNasdaq stockholm

Infant Bacterial Therapeutics AB (publ) Interim report January 1 – June 30, 2023

Infant Bacterial Therapeutics AB (publ) Interim report January 1 – June 30, 2023
itbusinessnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from itbusinessnet.com Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesMaria ekdahlStaffan stroData monitoring committeeEuropean patent officeAmerican journalSustained feeding toleranceExtraordinary general meetingBritish journalNasdaq stockholm

Extraordinary General Meeting of Infant Bacterial Therapeutics

At the Extraordinary General Meeting of Infant Bacterial Therapeutics AB on June 9, 2023, it was resolved to approve the Board of Directors’ resolution from May 16, 2023 to increase the. | June 9, 2023

Staffan stroMaria ekdahlExtraordinary general meetingInfant bacterial therapeuticsNasdaq stockholm

Annual General Meeting of Infant Bacterial Therapeutics

At the Annual General Meeting of Infant Bacterial Therapeutics AB on May 8, 2023, among other things, the following was resolved: to adopt the income statement and balance sheet and the consolidated. | May 8, 2023

Maria ekdahlAnthon jahreskogStaffan stroMargareta hagmanArticles of associationAudit committeeAnnual general meetingInfant bacterial therapeuticsPeter rothschildNominating committeeNasdaq stockholmInfant bacterial therapeutics ab publ stock exchangePress releaseHe ibtb se0008015259